Cubist Systematic Strategies LLC trimmed its position in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 30.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,391 shares of the biopharmaceutical company’s stock after selling 1,032 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Agios Pharmaceuticals were worth $160,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Crestline Management LP acquired a new position in Agios Pharmaceuticals in the 3rd quarter valued at $1,937,000. Capital International Investors grew its holdings in Agios Pharmaceuticals by 0.3% in the 3rd quarter. Capital International Investors now owns 3,138,131 shares of the biopharmaceutical company’s stock valued at $209,470,000 after buying an additional 8,294 shares in the last quarter. Brown Advisory Inc. grew its holdings in Agios Pharmaceuticals by 8.5% in the 3rd quarter. Brown Advisory Inc. now owns 291,139 shares of the biopharmaceutical company’s stock valued at $19,433,000 after buying an additional 22,736 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Agios Pharmaceuticals by 19.7% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 115,995 shares of the biopharmaceutical company’s stock valued at $7,743,000 after buying an additional 19,129 shares in the last quarter. Finally, Amalgamated Bank grew its holdings in Agios Pharmaceuticals by 12.9% in the 3rd quarter. Amalgamated Bank now owns 7,827 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 897 shares in the last quarter. 93.79% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Agios Pharmaceuticals Inc (NASDAQ AGIO) opened at $75.11 on Friday. The stock has a market capitalization of $3,536.64, a price-to-earnings ratio of -11.98 and a beta of 1.83. Agios Pharmaceuticals Inc has a 1-year low of $39.24 and a 1-year high of $76.02.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.78) by $0.19. The company had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. Agios Pharmaceuticals’s quarterly revenue was up 26.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.63) EPS. equities research analysts anticipate that Agios Pharmaceuticals Inc will post -6.59 EPS for the current year.
In other news, CEO David P. Schenkein sold 6,000 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $63.85, for a total transaction of $383,100.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Scott Biller sold 3,000 shares of the stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $65.00, for a total value of $195,000.00. Following the sale, the insider now directly owns 56,059 shares in the company, valued at $3,643,835. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,130 shares of company stock worth $2,039,260. 5.43% of the stock is currently owned by insiders.
AGIO has been the topic of a number of research reports. Oppenheimer set a $83.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 26th. ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. BidaskClub raised Agios Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 27th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $76.00 price objective on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $75.00.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.